NovoCure Ltd
NVCR- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001645113
In the last 90 days, NovoCure Ltd insiders filed 0 open-market purchases and 3 sales; 219 institutions reported holding it in 13F filings for Q2 2026, worth $1.57B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 13, 2026
- $1.38B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $142.8K in total
- 3
- 13F holdersQ2 2026, −3 vs. previous quarter
- 219
- 13F valueReported value at the end of Q2 2026
- $1.57B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $655.4M
- +8.3% year over year
- Net income, FY2025
- -$136.2M
- No comparable prior period
- Free cash flow, FY2025
- -$75.7M
- No comparable prior period
- Revenue, Q3 FY2026
- $193.4M
- +15.7% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $136.2M (20.8% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 12.9M
- Shares sold short
- Change
- +90.8K
- +0.7% vs. previous
- Days to cover
- 6.02
- At average daily volume
Superinvestors holding NVCR, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding NVCR at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by NovoCure Ltd insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 12, 2026 (view filing)4:07 PM ET | Nov 9 | 3 days | Paravasthu MukundChief Operating Officer | SSale | −3.08K | $12.86 | −$39.6K | −4.2%69.8K after | |
| Nov 12, 2026 (view filing)4:07 PM ET | Nov 9 | 3 days | Brackmann ChristophChief Financial Officer | SSale | −7.34K | $12.86 | −$94.4K | −4.0%175.5K after | |
| Nov 4, 2026 (view filing)4:05 PM ET | Nov 2 | 2 days | Puri Michal NathChief Human Resources Officer | SSale | −660 | $13.24 | −$8.74K | −0.3%202.6K after | |
| Jun 5, 2026 (view filing) | Jun 4 | 1 day | Leonard Frank XChief Executive Officer | SSale | −34.3K | $17.93 | −$614.5K | −6.9%459.5K after | |
| Jun 3, 2026 (view filing) | Jun 2 | 1 day | Stafford KristinDirector | SSale | −2.94K | $15.77 | −$46.4K | −20.6%11.3K after | |
| Jun 3, 2026 (view filing) | Jun 2 | 1 day | Ocean Allyson JDirector | SSale | −2.94K | $15.77 | −$46.4K | −20.6%11.3K after | |
| Jun 3, 2026 (view filing) | Jun 2 | 1 day | Scannell Timothy JDirector | SSale | −2.94K | $15.77 | −$46.4K | −17.1%14.3K after | |
| Jun 3, 2026 (view filing) | Jun 2 | 1 day | Vernon W AnthonyDirector | SSale | −2.94K | $15.77 | −$46.4K | −1.5%197.7K after | |
| Jun 3, 2026 (view filing) | Jun 2 | 1 day | Hung DavidDirector | SSale | −2.94K | $15.77 | −$46.4K | −12.6%20.5K after | |
| Jun 3, 2026 (view filing) | Jun 2 | 1 day | Leung GabrielDirector | SSale | −2.94K | $15.77 | −$46.4K | −3.2%89.5K after |
Top 10 13F holders, Q2 2026
See all 219 holdersThe largest institutional positions in NovoCure Ltd at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 17,373,078 | $263.2M | 0.01% | +303,929+1.8% | Added |
| BlackRock, Inc. | 13,413,699 | $203.2M | 0.00% | +219,934+1.7% | Added |
| Soleus Capital Management, L.P. | 9,913,401 | $150.2M | 5.18% | −578,990−5.5% | Reduced |
| Vanguard Portfolio Management LLC | 6,272,490 | $95.0M | 0.00% | +20,789+0.3% | Added |
| Vanguard Capital Management LLC | 4,903,633 | $74.3M | 0.00% | +221,569+4.7% | Added |
| Morgan Stanley | 4,522,389 | $68.5M | 0.00% | −19,137−0.4% | Reduced |
| State Street Corp | 2,866,546 | $43.4M | 0.00% | +304,729+11.9% | Added |
| Geode Capital Management, LLC | 2,798,351 | $42.4M | 0.00% | +286,644+11.4% | Added |
| Wells Fargo & Company | 2,528,093 | $38.3M | 0.01% | −423,144−14.3% | Reduced |
| Quantinno Capital Management LP | 2,223,455 | $33.7M | 0.04% | −263,921−10.6% | Reduced |
Holders of 5% or more of NVCR
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of NovoCure Ltd.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 8.30%9.08M shares | – | Apr 23, 20251 filing | Apr 23, 2025 | SEC |
| Soleus Capital Master Fund, L.P. | 13G/A | 8.10%9.43M shares | −1.00 ppfrom 9.10% | Apr 1, 20256 filings | Nov 9, 2026 | SEC |
| Vanguard Portfolio Management LLC | 13G | 5.57%6.34M shares | New | Apr 28, 20261 filing | Apr 28, 2026 | SEC |
Politician trades
All politician trades in NVCR2 members of Congress reported 3 trades in NovoCure Ltd since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Aug 5, 2021 |  Marie Newman House · IL | Buy | $15K-$50K |
| Apr 27, 2020 |  Donna E. Shalala House · FL | Sell | $1K-$15K |
| Apr 27, 2020 | Donna E. Shalala House · FL | Buy | $1K-$15K |
House · IL · Aug 5, 2021
Buy$15K-$50K
House · FL · Apr 27, 2020
Sell$1K-$15K
House · FL · Apr 27, 2020
Buy$1K-$15K